Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Joanna Jarosz, Katarzyna Miernik, Maria Wąchal, Jacek Walczak & Günther Krumpl. (2013) Naltrexone (50 mg) Plus Psychotherapy in Alcohol-Dependent Patients: A Meta-Analysis of Randomized Controlled Trials. The American Journal of Drug and Alcohol Abuse 39:3, pages 144-160.
Read now
Read now
Articles from other publishers (31)
Siobhan Botwright, Jiratorn Sutawong, Pritaporn Kingkaew, Thunyarat Anothaisintawee, Saudamini Vishwanath Dabak, Chotika Suwanpanich, Nattiwat Promchit, Roongnapa Kampang & Wanrudee Isaranuwatchai. (2023) Which interventions for alcohol use should be included in a universal healthcare benefit package? An umbrella review of targeted interventions to address harmful drinking and dependence. BMC Public Health 23:1.
Crossref
Crossref
Colby J. Hyland, Michal J. McDowell, Paul A. Bain, Haiden A. Huskamp & Alisa B. Busch. (2023) Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review. Journal of Substance Abuse Treatment 144, pages 108919.
Crossref
Crossref
Anita Srivastava, Sarah Clarke, Kate Hardy & Meldon Kahan. (2021) Facilitating rapid access to addiction treatment: a randomized controlled trial. Addiction Science & Clinical Practice 16:1.
Crossref
Crossref
Summer L. Thompson, Carol A. Gianessi, Stephanie S. O'Malley, Dana A. Cavallo, Julia M. Shi, Jeanette M. Tetrault, Kelly S. DeMartini, Ralitza Gueorguieva, Brian Pittman, John H. Krystal, Jane R. Taylor & Suchitra Krishnan-Sarin. (2021) Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. Frontiers in Psychiatry 12.
Crossref
Crossref
Leanne Trick & Bernard Le Foll. 2021. Textbook of Addiction Treatment. Textbook of Addiction Treatment
123
139
.
Przemyslaw Bienkowski, Marcin Wojnar, Pawel Mierzejewski, Jerzy Samochowiec, Boguslaw Habrat, Marek Jarema & Janusz Rybakowski. (2019) Long-term pharmacotherapy aimed at maintaining abstinence or reducing alcohol intake in alcohol-dependent individuals. Guidelines from the Section of Pharmacotherapy of Polish Society for Research on Addictions (PTBU) and the Section of Psychopharmacology of Polish Psychiatric Association (PTP) – 2019 update. Pharmacotherapy in Psychiatry and Neurology 35:2, pages 95-110.
Crossref
Crossref
Kerstin K Antonsen, Mette K Klausen, Amanda S Brunchmann, Nina le Dous, Mathias E Jensen, Kamilla Woznica Miskowiak, Patrick M Fisher, Gerda K Thomsen, Henrik Rindom, Thomas P Fahmy, Sabine Vollstaedt-Klein, Helene Benveniste, Nora D Volkow, Ulrik Becker, Claus Ekstrøm, Gitte Moos Knudsen, Tina Vilsbøll & Anders Fink-Jensen. (2018) Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open 8:7, pages e019562.
Crossref
Crossref
Amanda M. Barkley‐Levenson, Frances A. Lagarda & Abraham A. Palmer. (2018)
Glyoxalase 1 (GLO1) Inhibition or Genetic Overexpression Does Not Alter Ethanol's Locomotor Effects: Implications for
GLO
1 as a Therapeutic Target in Alcohol Use Disorders
. Alcoholism: Clinical and Experimental Research 42:5, pages 869-878.
Crossref
Crossref
Andrew C. Naglich, Austin Lin, Sidarth Wakhlu & Bryon H. Adinoff. (2017) Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions. CNS Drugs 32:1, pages 13-31.
Crossref
Crossref
Nicolas SimioniJulien LabreucheHélène BehalOlivier CottencinBenjamin Rolland. (2017) Thirty- Versus Ten-Day Diazepam Treatment for Alcohol Detoxification and a Comparison of Drinking Patterns, Craving, and Anxiety for up to 12 Weeks. Journal of Clinical Psychopharmacology 37:6, pages 722-728.
Crossref
Crossref
Falk Kiefer & Rilana Schuster. 2017. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
1489
1519
.
Falk Kiefer & Rilana Schuster. 2016. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
1
32
.
Stacia M. DeSantisHuirong Zhu. (2014) A Bayesian Mixed-Treatment Comparison Meta-analysis of Treatments for Alcohol Dependence and Implications for Planning Future Trials. Medical Decision Making 34:7, pages 899-910.
Crossref
Crossref
Liana R. N. Schreiber, Brian L. Odlaug & Jon E. Grant. (2013) The overlap between binge eating disorder and substance use disorders: Diagnosis and neurobiology. Journal of Behavioral Addictions 2:4, pages 191-198.
Crossref
Crossref
Anne Koopmann & Falk Kiefer. (2013) Alkoholabhängigkeit in der psychiatrischen KlinikAlcohol dependency in psychiatric clinics. Forensische Psychiatrie, Psychologie, Kriminologie 7:2, pages 114-121.
Crossref
Crossref
Doug Hyun Han, Sun Mi Kim, Jung Eun Choi, Kyung Joon Min & Perry F Renshaw. (2013) Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: Clinical and neuroimaging evidence. Journal of Psychopharmacology 27:3, pages 282-291.
Crossref
Crossref
Natalya C. Maisel, Janet C. Blodgett, Paula L. Wilbourne, Keith Humphreys & John W. Finney. (2012) Meta‐analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?. Addiction 108:2, pages 275-293.
Crossref
Crossref
Garmen A. Woo & Christopher O'Brien. (2012) Long-term Management of Alcoholic Liver Disease. Clinics in Liver Disease 16:4, pages 763-781.
Crossref
Crossref
Helga H. Lidö, Hugh Marston, Mia Ericson & Bo Söderpalm. (2011) The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598. Addiction Biology 17:5, pages 897-907.
Crossref
Crossref
Héctor José Navarro, Anthony Shakeshaft, Christopher M. Doran & Dennis J. Petrie. (2012) The cost-effectiveness of tailored, postal feedback on general practitioners’ prescribing of pharmacotherapies for alcohol dependence. Drug and Alcohol Dependence 124:3, pages 207-215.
Crossref
Crossref
M. Foster Olive, Richard M. Cleva, Peter W. Kalivas & Robert J. Malcolm. (2012) Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacology Biochemistry and Behavior 100:4, pages 801-810.
Crossref
Crossref
Falk Kiefer & Michael Soyka. 2012. Handbuch der Psychopharmakotherapie. Handbuch der Psychopharmakotherapie
733
749
.
Elizabeth M. Oliva, Natalya C. Maisel, Adam J. Gordon & Alex H. S. Harris. (2011) Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome Them. Current Psychiatry Reports 13:5, pages 374-381.
Crossref
Crossref
S. Campanella, G. Petit, P. Verbanck, C. Kornreich & X. Noel. (2011) How cognitive assessment through clinical neurophysiology may help optimize chronic alcoholism treatment. Neurophysiologie Clinique/Clinical Neurophysiology 41:3, pages 115-123.
Crossref
Crossref
F. Kiefer & M. Soyka. 2011. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
1341
1370
.
Angela Maria Ribeiro & Silvia R. Castanheira Pereira. 2011. Animal Models of Dementia. Animal Models of Dementia
665
683
.
Jose R. Maldonado. (2010) An Approach to the Patient with Substance Use and Abuse. Medical Clinics of North America 94:6, pages 1169-1205.
Crossref
Crossref
Richard J. Bodnar. (2009) Endogenous opiates and behavior: 2008. Peptides 30:12, pages 2432-2479.
Crossref
Crossref
John R. Hughes. (2009) How confident should we be that smoking cessation treatments work?. Addiction 104:10, pages 1637-1640.
Crossref
Crossref
Hui‐Hui Tan, Sharad Virmani & Paul Martin. (2009) Controversies in the Management of Alcoholic Liver Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:5, pages 484-498.
Crossref
Crossref
Kenneth Blum, Amanda LihChuan Chen, Thomas JH Chen, Eric R Braverman, Jeffrey Reinking, Seth H Blum, Kimberly Cassel, Bernard W Downs, Roger L Waite, Lonna Williams, Thomas J Prihoda, Mallory M Kerner, Tomas Palomo, David E Comings, Howard Tung, Patrick Rhoades & Marlene Oscar-Berman. (2008) Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theoretical Biology and Medical Modelling 5:1.
Crossref
Crossref